We will be in contact shortly.
– KX technology to support BrainWaveBank as it uses AI to transform cognitive health –
– Solutions based on KX will allow individuals to monitor their cognitive health and allow BrainWaveBank to develop systems capable of screening for early signs of conditions such as Alzheimer’s disease –
– Using AI, the platform will analyse large datasets to analyse causal effects of cognitive decline and assist in the development of drugs and therapies in a market valued at $8 billion by 2021 –
Global technology specialist FD announces that BrainWaveBank, an innovative start-up focused on cognitive health, has selected KX technology to power its neuroscience platform. The agreement will allow BrainWaveBank to build the world’s first Big Data collection of brainwave activity data and to target the cognitive health assessment market, expected to reach US$ 8.1 billion in 2021, according to analysts MarketsandMarkets.
Currently, 90% of people who suffer from cognitive health disorders are diagnosed many years too late or not at all and the incidence of Alzheimer’s alone is expected to triple to 130 million people by 2050. It is estimated that early detection and intervention can delay onset of the disease and reduce the cost of care by 35% or more. BrainWaveBank’s solution, developed by a team of neuroscientists, cognitive psychologists, machine learning and big data analytics specialists, is to provide the ability for individuals to track their own cognitive performance – and analyse it for anomalies relative to their own history and the data generated by other users within their demographic.
To achieve this BrainWaveBank has developed a low cost, high resolution brainwave (EEG) scanning headset that can be worn at home while playing engaging mobile games for a few minutes a day, several times per week. The data can be adjusted for factors such as medication, sleep and activity and the aggregated data is used to establish healthy baselines for different demographics. As well as monitoring individual cognitive health, BrainWaveBank also intends to address the £800m per annum market for clinical trial support, helping pharma companies to identify trial candidates for drugs targeted at the early stages of neurodegenerative diseases.
KX will power the neuroscience platform that analyses the data, which will build into the world’s first ever database of brainwave activity recorded daily in the home. The use of KX will allow real-time analytics to be conducted on brainwave activity and will accelerate analysis of aggregated data.
Ronan Cunningham, Chief Executive Officer of BrainWaveBank commented: “Through its ability to rapidly process vast amounts of time-series data, provide analytics in real-time, and integrate with our machine learning pipelines, KX is ideally placed to power our neuroscience platform. It also has the ability to scale seamlessly to support our plan to create the largest and most valuable database of EEG data, tagged with demographic, behavioural and lifestyle information, that has ever been assembled.”
Brian Conlon, Chief Executive Officer of KX commented: “BrainWaveBank is led by experienced computational neuroscience and cognitive psychology experts with a business development road map that is capable of transforming the way cognitive health is measured and treated. Combining this domain expertise with our KX technology has the potential to deliver new insights in this important area of healthcare.”
|For further information please contact:|
|0845 370 7024|
KX is a division of FD, a global technology provider with 20 years of experience working with some of the world’s largest finance, technology, retail, pharma, manufacturing and energy institutions. KX technology, incorporating the kdb+ time-series database, is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. KX delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications across multiple industries. The Group operates from 14 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 1,800 people worldwide.
BrainWaveBank’s goal is to build the world’s largest collection of brain activity data to support a transformation in the detection and treatment of cognitive illness. Specially-designed games and innovative brain-reading technologies measure subtle changes in cognitive performance, while machine learning methods decode these recordings to give new insights into how your brain works. BrainWaveBank’s technology allows anyone to measure and track their cognitive health at home in just a few minutes a day, helping transform our understanding of brain health so that people can live longer, healthier lives.
For more information about BrainWaveBank visit www.brainwavebank.com